[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640446":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":36,"responsibleParty":57,"collaborators":11,"id":59,"slug":11,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Shandong Suncadia Medicine Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS-7156","EXPERIMENTAL",null,[13],"Drug: HRS-7156",{"label":15,"type":16,"description":11,"interventionNames":17},"HRS-7156 placebo","PLACEBO_COMPARATOR",[18],"Drug: HRS-7156 placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","HRS-7156, specified dose on specified day.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"HRS-7156 placebo, specified dose on specified day.",[15],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Kaiyun Zhang","CONTACT","+86-0518-82342973","kaiyun.zhang.kz38@hengrui.com",{"name":34,"role":30,"phone":31,"phoneExt":11,"email":35},"Sheng Qi","sheng.qi@hengrui.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Zhongshan Hospital Affiliated to Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200032","China",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51,55],{"name":52,"role":30,"phone":53,"phoneExt":11,"email":54},"Xuening Li","+86-021-31587862","li.xuening@zs-hospital.sh.cn",{"name":52,"role":56,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640446",false,"NCT07601087","A Clinical Study of HRS-7156 in Healthy Participants","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of HRS-7156 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 55 years old at informed consent signing;\n2. Male body weight ≥50 kg, female ≥45 kg; BMI 18.5 to 30 kg\u002Fm² at screening and baseline;\n3. Have no clinically significant abnormalities at screening and baseline;\n4. Fertile females and males with fertile female partners: effective contraception 2 weeks before consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation.\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results;\n2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial;\n3. Blood donation\u002Fsevere blood loss (≥400 mL) within 8 weeks, blood transfusion within 4 weeks before screening; planned blood donation during the trial;\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening.Participation in other clinical trials within 3 months before screening or planned;\n5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer);\n6. Smoking history (≥5 cigarettes\u002Fday) within 4 weeks before screening; inability to abstain from tobacco during the trial; positive smoke screening at screening\u002Fbaseline;\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening;\n8. Special dietary requirements and inability to comply with the unified diet;\n9. Difficulty in swallowing\u002Fvenous blood collection; intolerance to intensive blood sampling;\n10. Other circumstances deemed unsuitable for trial participation by Researcher.",true,"ALL","18 Years","55 Years",{"count":70,"type":71},66,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.",[77],"Heart Failure","2026-06-25",{"date":80,"type":81},"2026-06-29","ACTUAL",{"date":83,"type":71},"2026-06-12",{"date":85,"type":71},"2026-07",{"name":5,"class":6},1]